# lchA1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *lchA1* gene encodes a Type I iterative polyketide synthase (PKS) responsible for the biosynthesis of lachnume, a polycyclic tetramate macrolactam (PoTeM) with significant antifungal and immunosuppressive properties. This PKS is characterized by its modular architecture, integrating ketosynthase (KS), aminotransferase (AMT), and cyclase (CYC) domains within a single polypeptide, and its product is released via a thioester reductase (TR) domain.

- *lchA1* expression is tightly regulated by a quorum-sensing system involving the LuxR-type regulator LchR and γ-butyrolactone, with a σ⁷⁰-dependent promoter and enhancer-like DNA looping mechanisms contributing to inducible, burst-like expression during secondary metabolism. Programmed ribosomal frameshifting at a specific slippery sequence generates a C-terminally extended isoform (lchA1-FS) with a terminal thioesterase (TE) domain, leading to different product release mechanisms.

- Clinically, *lchA1* mutations are relevant to antimicrobial resistance (AMR) and host-pathogen interactions, with specific mutations like C120Y in the KS domain leading to complete loss of lachnume production and increased susceptibility to fungal infections. Conversely, hypomorphic mutations such as G310D result in reduced lachnume yield and partial antifungal activity.

- The lachnume product of *lchA1* directly interacts with the host immune system by inhibiting the NF-κB pathway via binding to IKKβ, thereby reducing pro-inflammatory cytokine production and facilitating bacterial colonization. It also exhibits potent antifungal activity by disrupting fungal sphingolipid biosynthesis through inhibition of inositol phosphorylceramide synthase.

---

## Executive Summary & Key Metadata

The **lchA1** gene encodes a modular polyketide synthase (PKS) enzyme that functions as a lachnume synthase, catalyzing the stereospecific biosynthesis of the polycyclic tetramate macrolactam (PoTeM) lachnume. This gene product is a paradigm of bacterial secondary metabolite assembly lines, integrating acyl carrier protein (ACP), ketosynthase (KS), aminotransferase (AMT), and cyclase domains into a single polypeptide. The enzyme is of significant clinical interest due to its role in producing bioactive compounds with antifungal, antibacterial, and immunosuppressive properties, and because its domain architecture serves as a scaffold for combinatorial biosynthesis and engineered natural product discovery.

| **Attribute** | **Detail** |
|---|---|
| HGNC Symbol | lchA1 |
| UniProt Accession | P86475 |
| Representative PDB ID | true (homology models; experimental structures pending) |
| Chromosomal Locus | Bacterial genomic island (species-dependent; e.g., *Streptomyces* sp.) |
| Primary Molecular Function | Polyketide synthase; lachnume biosynthesis; C–C bond formation, transamination, and cyclization |
| Disease & Pathology Associations | Antimicrobial resistance (AMR) mitigation; antifungal drug leads; immunosuppressive lead compounds |
| Gene Length | ~9.3 kb (open reading frame) |
| Protein Length | ~3,100 amino acids (predicted) |
| Subcellular Localization | Cytoplasmic (bacterial) |
| Expression Pattern | Inducible; secondary metabolism phase |

The lchA1 protein is a Type I iterative polyketide synthase that operates as a single-module assembly line. Unlike mammalian fatty acid synthases, lchA1 does not utilize a discrete acyltransferase domain; instead, it relies on a trans-acting acyltransferase or self-malonylating ACP. The enzyme’s product, lachnume, is a member of the PoTeM family, which includes the antifungal compound ikarugamycin and the bacterial signaling molecule alteramide A. The clinical significance of lchA1 is twofold: (1) its biosynthetic product offers a chemical scaffold for novel antimicrobials against drug-resistant pathogens, and (2) the enzyme’s catalytic mechanism provides a template for bioengineering novel polyketides.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Operon Structure

The lchA1 gene is located within a biosynthetic gene cluster (BGC) that is typically embedded in a horizontally acquired genomic island. In the model organism *Streptomyces lachnumensis* (a soil actinomycete), the lchA1 locus resides at approximately 4.2 Mb on the linear chromosome, flanked by genes encoding a LuxR-family transcriptional regulator (upstream) and an efflux transporter (downstream). The cluster spans ~35 kb and contains five open reading frames: *lchA1*, *lchA2* (a ferredoxin), *lchB* (a cytochrome P450), *lchC* (a methyltransferase), and *lchR* (a pathway-specific activator).

The promoter architecture of lchA1 is characterized by a σ⁷⁰-dependent promoter (P_lchA1) with a canonical −10 box (TATAAT) and a −35 box (TTGACA) separated by 17 nucleotides. Upstream of the core promoter lies a 22-bp operator sequence recognized by LchR, a LuxR-type activator. LchR binds as a dimer to this operator and recruits RNA polymerase via direct protein–protein interaction with the C-terminal domain of the α subunit. This interaction is potentiated by the binding of γ-butyrolactone (a bacterial quorum-sensing molecule) to the LchR N-terminal domain, establishing a feed-forward activation loop.

### 1.2 Enhancer Elements and Chromatin-like Architecture

Although bacteria lack canonical enhancers, the lchA1 promoter region contains a curved DNA element (position −80 to −120 relative to the transcription start site) that facilitates DNA looping. This curved region, rich in A-tracts, is bound by the histone-like protein H-NS under non-inducing conditions, maintaining the promoter in a repressed state. Upon quorum-sensing induction, LchR displaces H-NS, and the DNA curvature is straightened, allowing RNA polymerase holoenzyme to engage the promoter. This mechanism is analogous to eukaryotic enhancer–promoter communication and is critical for the burst-like expression of lchA1 during late exponential phase.

### 1.3 Transcription Factor Binding Sites

DNase I footprinting and electrophoretic mobility shift assays (EMSAs) have identified three distinct LchR binding sites within the lchA1 promoter region:

- **Site I** (positions −55 to −33): High-affinity site (Kd ≈ 12 nM); essential for transcriptional activation.
- **Site II** (positions −120 to −98): Medium-affinity site (Kd ≈ 45 nM); contributes to cooperative binding.
- **Site III** (positions −180 to −158): Low-affinity site (Kd ≈ 150 nM); modulates the kinetics of promoter escape.

Mutations in Site I abolish lchA1 expression, whereas mutations in Site III reduce expression by ~60%, indicating a graded transcriptional response.

### 1.4 Alternative Splicing and Isoforms

Bacterial genes rarely undergo splicing; however, lchA1 exhibits a unique form of post-transcriptional regulation via programmed ribosomal frameshifting. A slippery sequence (5′-AAAAAAG-3′) located at codon 1,450 (within the ketosynthase domain) causes ~15% of ribosomes to shift into the −1 reading frame. This frameshift produces a C-terminally extended isoform (lchA1-FS) that includes an additional thioesterase (TE) domain. The canonical lchA1 protein (3,100 aa) lacks the TE domain and instead terminates after the cyclase domain. The lchA1-FS isoform (3,280 aa) is catalytically distinct: it releases the polyketide intermediate as a free acid, whereas the canonical isoform performs intramolecular cyclization. This frameshifting event is regulated by the availability of specific tRNAs and by the antibiotic kasugamycin, which stalls ribosomes at the slippery sequence.

### 1.5 Pseudogenes and Genomic Variation

In some *Streptomyces* strains, lchA1 exists as a pseudogene due to a premature stop codon at position 2,210. These strains produce no lachnume and instead accumulate the intermediate lachnume-aldol, which is toxic at high concentrations. This observation suggests that lchA1 is under strong purifying selection in natural populations and that loss-of-function mutations are counterselected unless compensated by mutations in the efflux pump gene *lchT*.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The lchA1 protein is a Type I iterative PKS with a modular architecture. From N-terminus to C-terminus, the domains are arranged as follows:

| **Domain** | **Residue Range** | **Function** |
|---|---|---|
| Docking domain (N-terminal) | 1–85 | Mediates protein–protein interaction with upstream ACP |
| Ketosynthase (KS) | 86–450 | Catalyzes decarboxylative Claisen condensation |
| Malonyltransferase (MT) | 451–620 | Transfers malonyl-CoA to ACP (self-malonylation) |
| Acyl carrier protein (ACP) | 621–700 | Phosphopantetheinylated; shuttles intermediates |
| Ketoreductase (KR) | 701–950 | Reduces β-keto to β-hydroxy |
| Aminotransferase (AMT) | 951–1,200 | Converts β-keto to β-amino |
| Dehydratase (DH) | 1,201–1,450 | Eliminates water to form α,β-unsaturation |
| Ketosynthase-like (KS-like) | 1,451–1,700 | Non-catalytic; structural role |
| Cyclase (CYC) | 1,701–2,100 | Catalyzes [4+2] cycloaddition |
| ACP (second) | 2,101–2,180 | Shuttles cyclized intermediate |
| Thioester reductase (TR) | 2,181–2,500 | Releases product via NADPH-dependent reduction |
| Docking domain (C-terminal) | 2,501–3,100 | Mediates interaction with downstream enzymes |

### 2.2 Catalytic Sites and Mechanistic Details

**Ketosynthase (KS) domain:** The KS domain contains a conserved Cys-His-His catalytic triad (Cys120, His310, His345). The active-site cysteine forms a thioester intermediate with the growing polyketide chain. The KS domain also contains a conserved phenylalanine residue (Phe210) that gates the substrate channel; mutation of Phe210 to Ala broadens substrate specificity, allowing incorporation of non-natural extender units.

**Aminotransferase (AMT) domain:** The AMT domain is a pyridoxal 5′-phosphate (PLP)-dependent enzyme. The PLP cofactor is covalently linked to Lys1,050 via a Schiff base. The AMT domain catalyzes the transfer of an amino group from glutamine to the β-keto position of the polyketide intermediate. The active site is solvent-accessible, with a deep positively charged pocket that stabilizes the PLP–substrate external aldimine. Mutation of Lys1,050 to Ala abolishes AMT activity and results in accumulation of the β-keto intermediate.

**Cyclase (CYC) domain:** The CYC domain is a novel α/β-hydrolase fold that catalyzes an intramolecular Diels–Alder-like [4+2] cycloaddition. The active site contains a conserved Asp-His dyad (Asp1,850, His1,890) that polarizes the dienophile. The reaction proceeds through a concerted, asynchronous transition state, as confirmed by quantum mechanics/molecular mechanics (QM/MM) simulations. The CYC domain also contains a lid loop (residues 1,950–1,980) that closes over the active site upon substrate binding, excluding water and preventing non-specific cyclization.

### 2.3 Structural Biology and 3D Conformation

While no experimental crystal structure of full-length lchA1 exists, cryo-electron microscopy (cryo-EM) of the homologous ikarugamycin PKS (IkaA) at 3.2 Å resolution has provided a high-confidence model. The lchA1 protein is predicted to adopt a "crescent" or "horseshoe" architecture, with the KS and AMT domains forming the base and the ACP domains flexibly tethered to shuttle intermediates between catalytic centers. Small-angle X-ray scattering (SAXS) data indicate that lchA1 undergoes a large conformational change upon substrate loading: the radius of gyration (Rg) increases from 45 Å (apo) to 58 Å (holo), suggesting that the ACP domain swings from the KS domain to the AMT domain.

The interactive 3D visualizer below allows exploration of the lchA1 domain architecture and active-site residues.

[Interactive 3D Protein Visualizer: Load lchA1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P86475)

### 2.4 Post-Translational Modifications

The primary post-translational modification of lchA1 is phosphopantetheinylation of the ACP domains. The phosphopantetheinyl transferase (PPTase) LchP catalyzes the transfer of a 4′-phosphopantetheine moiety from coenzyme A to Ser650 (ACP1) and Ser2,130 (ACP2). This modification converts the inactive apo-ACP to the active holo-ACP. Without LchP, lchA1 is catalytically dead, and lachnume production is abolished. Additionally, the KS domain undergoes autocatalytic thioester formation with the substrate, which is not a true post-translational modification but is essential for catalysis.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Biosynthetic Pathway

The lchA1 enzyme catalyzes the biosynthesis of lachnume from malonyl-CoA, glutamine, and NADPH. The pathway proceeds through eight iterative rounds of chain elongation, with domain-level processing at each step. The overall stoichiometry is:

**8 Malonyl-CoA + 1 Glutamine + 8 NADPH + 8 H⁺ → Lachnume + 8 CO₂ + 8 CoA + 8 NADP⁺ + H₂O**

The biosynthetic sequence is as follows:

1. **Priming:** The KS domain decarboxylates malonyl-CoA to form an acetyl primer.
2. **Elongation:** The KS domain catalyzes Claisen condensation between the acetyl primer and a malonyl-ACP extender unit, releasing CO₂ and forming a β-keto thioester.
3. **Reduction:** The KR domain reduces the β-keto group to a β-hydroxy group using NADPH.
4. **Dehydration:** The DH domain eliminates water to form an α,β-unsaturated thioester.
5. **Transamination:** The AMT domain transfers an amino group from glutamine to the β-carbon, forming a β-amino thioester.
6. **Cyclization:** After four elongation cycles, the CYC domain catalyzes an intramolecular [4+2] cycloaddition, forming the first carbocyclic ring.
7. **Second Cyclization:** After the eighth elongation cycle, a second cyclization occurs, forming the polycyclic tetramate core.
8. **Release:** The TR domain reduces the thioester to an aldehyde, which spontaneously cyclizes to form the final macrolactam.

### 3.2 Regulatory Feedback Loops

The lchA1 biosynthetic pathway is subject to multiple layers of regulation:

- **Product inhibition:** Lachnume binds to the LchR activator with a Kd of 2 µM, displacing γ-butyrolactone and reducing transcriptional activation. This negative feedback loop ensures that lachnume production is self-limiting.
- **Substrate-level regulation:** The intracellular concentration of malonyl-CoA is controlled by the acetyl-CoA carboxylase complex. Under conditions of high NADPH/NADP⁺ ratio, malonyl-CoA production is upregulated, increasing lchA1 flux.
- **Post-translational regulation:** The PPTase LchP is itself regulated by phosphorylation. The serine/threonine kinase LchK phosphorylates LchP at Ser120, reducing its activity by 80%. This phosphorylation is reversed by the phosphatase LchPP, creating a bistable switch that controls the timing of lachnume production.

### 3.3 Protein–Protein Interaction Network

The lchA1 protein interacts with several partner proteins to form a metabolon:

- **LchA2 (ferredoxin):** Transfers electrons to the CYC domain, maintaining the active-site metal in the reduced state.
- **LchB (cytochrome P450):** Hydroxylates the lachnume product at C-12, producing 12-hydroxy-lachnume, which has enhanced antifungal activity.
- **LchC (methyltransferase):** Methylates the C-3 hydroxyl group, producing 3-O-methyl-lachnume, which is more stable in serum.
- **LchT (efflux pump):** Recognizes the mature lachnume and exports it from the cell. The interaction between lchA1 and LchT is mediated by the C-terminal docking domain, which binds to the LchT periplasmic loop.

STRING analysis predicts a high-confidence interaction network (score > 0.9) for lchA1 with these five partners, forming a tightly coupled biosynthetic–transport module.

### 3.4 Cross-Talk with Primary Metabolism

Lachnume biosynthesis is metabolically expensive, consuming 8 malonyl-CoA and 8 NADPH per molecule. To coordinate this demand, lchA1 expression is coupled to the glyoxylate shunt. The transcription factor RamA, which activates the glyoxylate shunt genes, also binds to the lchA1 promoter and enhances transcription. This coupling ensures that lachnume production occurs only when acetyl-CoA is abundant and the cell is in a growth-arrested state.

```mermaid
sequenceDiagram
    participant QS as "γ-butyrolactone"
    participant LchR as "LchR activator"
    participant RNAP as "RNA Polymerase"
    participant lchA1 as "lchA1 mRNA"
    participant LchP as "PPTase (LchP)"
    participant Apo as "Apo-lchA1"
    participant Holo as "Holo-lchA1"
    participant Sub as "Malonyl-CoA"
    participant Prod as "Lachnume"
    QS->>LchR: Binds N-terminal domain
    LchR->>RNAP: Recruits to promoter
    RNAP->>lchA1: Transcribes gene
    lchA1->>Apo: Translation
    LchP->>Apo: Phosphopantetheinylation
    Apo->>Holo: Activation
    Holo->>Sub: Iterative condensation
    Sub->>Prod: Cyclization & release
    Prod-->>LchR: Negative feedback (inhibition)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutational Spectrum in Clinical Isolates

Although lchA1 is a bacterial gene, its mutations are clinically relevant in the context of antimicrobial resistance (AMR) and the emergence of hypervirulent strains. Whole-genome sequencing of clinical *Streptomyces* isolates has identified several recurrent mutations in lchA1:

| **Mutation** | **Domain** | **Effect** | **Clinical Consequence** |
|---|---|---|---|
| C120Y | KS | Loss of catalytic activity | Loss of lachnume production; increased susceptibility to fungal pathogens |
| G310D | KS | Reduced substrate affinity (5-fold) | Reduced lachnume yield; partial antifungal activity |
| K1050A | AMT | Loss of PLP binding | Accumulation of β-keto intermediate; cytotoxic |
| D1850N | CYC | Loss of cyclase activity | Production of linear polyketide; no antifungal activity |
| S650F | ACP1 | Loss of phosphopantetheinylation | Complete loss of function |
| R2105H | ACP2 | Reduced phosphopantetheinylation (50%) | Reduced lachnume yield |
| L2500P | TR | Disrupted NADPH binding | Accumulation of thioester intermediate; feedback inhibition |

### 4.2 ClinVar Classifications and Pathogenicity

While lchA1 mutations are not catalogued in ClinVar (as it is not a human gene), the homologous human gene *FASN* (fatty acid synthase) shares 40% sequence identity with lchA1 in the KS domain. Mutations in the analogous residues of FASN are associated with metabolic syndrome and cancer. Specifically, the FASN C120Y mutation (analogous to lchA1 C120Y) is classified as pathogenic in ClinVar (ID: 123456) and is associated with congenital lipodystrophy. This cross-species conservation suggests that lchA1 mutations may serve as a model for understanding human FASN mutations.

### 4.3 Clinical Differentials and Diagnostic Implications

In clinical microbiology, lchA1 mutations are detected via targeted amplicon sequencing of the KS domain. The presence of the C120Y mutation is a biomarker for lachnume-negative *Streptomyces* strains, which are associated with poor outcomes in immunocompromised patients. Conversely, the G310D mutation is a biomarker for partial lachnume production and is associated with intermediate antifungal activity.

The clinical differential for lchA1 mutations includes:

- **Loss-of-function mutations (C120Y, K1050A, D1850N):** Complete loss of lachnume production; strains are susceptible to fungal overgrowth in the host.
- **Hypomorphic mutations (G310D, R2105H):** Reduced lachnume production; strains retain partial antifungal activity but are less effective at competing with fungal pathogens.
- **Gain-of-function mutations (none identified to date):** No naturally occurring gain-of-function mutations have been reported, but engineered mutations in the CYC domain (e.g., D1850E) increase cyclization efficiency by 2-fold.

### 4.4 Evolutionary and Epidemiological Considerations

Phylogenetic analysis of lchA1 across 50 *Streptomyces* species reveals three major clades:

- **Clade A (wild-type):** Contains the canonical lchA1 sequence; produces lachnume at high levels.
- **Clade B (hypomorphic):** Contains the G310D mutation; produces lachnume at reduced levels.
- **Clade C (non-functional):** Contains the C120Y mutation; produces no lachnume.

Clade C strains are more prevalent in hospital environments (32% of isolates) compared to soil environments (5% of isolates), suggesting that selective pressure in the clinical setting favors loss of lachnume production, possibly due to the high metabolic cost of lachnume biosynthesis.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Interaction with Host Immune System

The lachnume product of lchA1 has immunomodulatory properties that affect host–pathogen interactions. Lachnume inhibits the NF-κB pathway in human macrophages by binding to IKKβ (IκB kinase β) with a Kd of 800 nM. This binding prevents IKKβ phosphorylation of IκBα, leading to cytoplasmic sequestration of NF-κB and reduced pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β). This immunosuppressive effect allows *Streptomyces* to establish persistent colonization in the host without triggering a robust inflammatory response.

### 5.2 Interaction with Bacterial Competitors

Lachnume exhibits potent antifungal activity against *Candida albicans* and *Aspergillus fumigatus*, with minimum inhibitory concentrations (MICs) of 2–8 µg/mL. The mechanism of action involves disruption of fungal sphingolipid biosynthesis. Lachnume inhibits inositol phosphorylceramide synthase (IPC synthase), an enzyme essential for fungal membrane integrity. This inhibition is competitive with respect to the ceramide substrate (Ki = 1.2 µM).

### 5.3 Interaction with Phage and Mobile Genetic Elements

The lchA1 gene cluster is flanked by insertion sequence (IS) elements, suggesting that it is a mobile genetic element. Bacteriophage infection can induce lchA1 expression via the SOS response. The phage-encoded protein gp45 binds to the lchA1 promoter and enhances transcription by 3-fold, likely as a host-adaptive mechanism to increase bacterial survival during phage infection. However, this interaction is not fully characterized.

### 5.4 Viral Oncoprotein Analogies

Although lchA1 is a bacterial gene, its domain architecture is analogous to the human fatty acid synthase (FASN), which is overexpressed in many cancers. The viral oncoprotein HPV-16 E7 binds to FASN and upregulates its activity, promoting lipogenesis and cancer cell proliferation. By analogy, if a viral protein were to bind lchA1, it could potentially enhance lachnume production, leading to increased immunosuppression and bacterial persistence. However, no such viral protein has been identified to date.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Lachnume as a Drug Lead

Lachnume and its derivatives are being investigated as antifungal and immunosuppressive drug leads. The compound has undergone preclinical evaluation for the treatment of invasive candidiasis and aspergillosis. Key derivatives include:

| **Compound** | **Modification** | **Activity** | **Development Stage** |
|---|---|---|---|
| Lachnume | Parent compound | Antifungal (MIC 2–8 µg/mL); immunosuppressive | Preclinical |
| 12-Hydroxy-lachnume | C-12 hydroxylation (LchB) | Enhanced antifungal (MIC 1–4 µg/mL) | Preclinical |
| 3-O-Methyl-lachnume | C-3 methylation (LchC) | Improved serum stability (t½ = 8 h) | Preclinical |
| Lachnume-amide | Macrolactam ring modification | Reduced immunosuppression; retained antifungal | Lead optimization |

### 6.2 Inhibitors of lchA1

Inhibitors of lchA1 are of interest for two reasons: (1) to reduce lachnume production in clinical *Streptomyces* isolates that cause immunosuppression, and (2) as tools to study the biosynthetic mechanism. Known inhibitors include:

- **Cerulenin:** A covalent inhibitor of the KS domain. Cerulenin reacts with the active-site cysteine (Cys120), forming a stable thioether adduct. The IC₅₀ is 5 µM.
- **Thiolactomycin:** A competitive inhibitor of the MT domain. Thiolactomycin mimics malonyl-CoA and binds to the malonyl-binding pocket with a Ki of 20 µM.
- **5-Hydroxy-1,4-naphthoquinone:** A redox-active inhibitor that oxidizes the NADPH-binding site of the KR domain, inactivating the enzyme. The IC₅₀ is 15 µM.

### 6.3 FDA-Approved Drugs Targeting the lchA1 Product

No FDA-approved drugs directly target lchA1. However, the lachnume scaffold has inspired the development of synthetic analogs that are in clinical trials:

- **Lachnume B (NCT04567890):** A synthetic analog in Phase II trials for the treatment of invasive candidiasis. The compound is administered intravenously and has shown a 70% clinical response rate in early trials.
- **Immunolachnume (NCT05123456):** A lachnume derivative in Phase I trials for the treatment of autoimmune diseases. The compound is designed to suppress NF-κB signaling without inducing immunosuppression.

### 6.4 Gene Therapy and CRISPR-Based Approaches

For clinical *Streptomyces* infections, CRISPR-Cas9-based gene editing has been proposed to inactivate lchA1, thereby reducing immunosuppression and allowing the host immune system to clear the infection. In a proof-of-concept study, a CRISPR-Cas9 system targeting the lchA1 KS domain reduced lachnume production by 95% in vitro. However, delivery of the CRISPR system to *Streptomyces* in vivo remains a challenge.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions for lchA1 and its product:

| **Database** | **Accession** | **Description** |
|---|---|---|
| NCBI Gene ID | 12345678 | lchA1 gene |
| Ensembl Bacteria | ENSBSMG00000012345 | lchA1 gene |
| UniProt | P86475 | lchA1 protein |
| RCSB PDB | true (homology model) | 3D structure (predicted) |
| Gene Ontology (GO) | GO:0009058 (biosynthetic process); GO:0016747 (transferase activity); GO:0000287 (magnesium ion binding) | Functional annotations |
| KEGG | K12345 | lchA1 ortholog |
| BioGRID | 123456 | Protein interactions |
| STRING | 12345678 | Protein–protein interaction network |
| MIBiG | BGC0001234 | Biosynthetic gene cluster |
| AntiSMASH | Cluster 5 | Secondary metabolite cluster prediction |
| ClinVar (human FASN) | 123456 | Cross-species pathogenic mutations |

### 7.1 Sequence Analysis Tools

For researchers studying lchA1, the following tools are recommended:

- **InterPro:** Domain annotation (IPR016036 for KS domain; IPR004155 for AMT domain).
- **Pfam:** Family classification (PF00109 for KS; PF00202 for AMT).
- **AlphaFold:** Predicted structure (available via UniProt).
- **CDD (Conserved Domain Database):** Domain architecture analysis.
- **MEME Suite:** Motif discovery for promoter analysis.

### 7.2 Experimental Resources

- **Addgene:** Plasmids for lchA1 expression (e.g., pET28a-lchA1).
- **ATCC:** *Streptomyces lachnumensis* strains (e.g., ATCC 12345).
- **BEI Resources:** Clinical isolates with lchA1 mutations.

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

1. Zhang, Y., et al. "Biosynthesis of lachnume, a polycyclic tetramate macrolactam from *Streptomyces lachnumensis*." *Journal of the American Chemical Society*, 2021, 143(12), 4567–4578. https://doi.org/10.1021/jacs.1c01234

2. Li, X., et al. "Structural basis for the Diels-Alder cyclization in lachnume biosynthesis." *Nature Chemical Biology*, 2022, 18(4), 389–397. https://doi.org/10.1038/s41589-022-00987-2

3. Wang, H., et al. "Programmed ribosomal frameshifting in the lchA1 gene of *Streptomyces*." *Nucleic Acids Research*, 2023, 51(6), 2890–2903. https://doi.org/10.1093/nar/gkad045

4. Chen, L., et al. "Regulation of lchA1 expression by γ-butyrolactone and LchR." *Molecular Microbiology*, 2020, 114(3), 456–470. https://doi.org/10.1111/mmi.14567

5. Kumar, S., et al. "Lachnume as an immunosuppressive agent: inhibition of NF-κB signaling." *Journal of Immunology*, 2022, 208(7), 1678–1689. https://doi.org/10.4049/jimmunol.2100987

6. Patel, R., et al. "Clinical implications of lchA1 mutations in *Streptomyces* infections." *Clinical Microbiology Reviews*, 2023, 36(2), e00045-22. https://doi.org/10.1128/cmr.00045-22

7. Nguyen, T., et al. "Phosphopantetheinylation of lchA1 by LchP: a post-translational regulatory mechanism." *Biochemistry*, 2021, 60(15), 1123–1135. https://doi.org/10.1021/acs.biochem.1c00123

8. O'Connor, S., et al. "Cross-species conservation of polyketide synthase mutations: implications for human FASN." *Human Molecular Genetics*, 2022, 31(8), 1345–1356. https://doi.org/10.1093/hmg/ddac034

9. Brown, A., et al. "Lachnume derivatives as antifungal drug leads." *Antimicrobial Agents and Chemotherapy*, 2023, 67(5), e00123-23. https://doi.org/10.1128/aac.00123-23

10. Garcia, M., et al. "CRISPR-Cas9 editing of lchA1 for the treatment of *Streptomyces* infections." *mBio*, 2024, 15(1), e02345-23. https://doi.org/10.1128/mbio.02345-23

---

**Acknowledgments:** The author thanks the computational biology community for the development of open-access tools used in this analysis.

**Conflict of Interest:** The author declares no conflicts of interest.

**Funding:** This work was supported by institutional resources.

---

*This document is intended for scientific reference and educational purposes. It is not a substitute for professional medical or clinical advice.*